title: Increased atrial vulnerability in arrhythmogenic right ventricular disease.
abstract: Supraventricular tachyarrhythmias (SVTA) may occur in patients with the arrhythmogenic right ventricular dysplasia (ARVD). The purpose of the study was to evaluate the incidence of SVTA in 47 patients with ARVD proved by right ventricular angiography. Thirty-three men and 14 women, aged 21 to 72 years (mean 44 +/- 18) were admitted for nonsustained or sustained ventricular tachycardia. Eight patients had a history of spontaneous SVTA several years before ventricular tachycardia occurrence. Protocol of the study consisted of programmed atrial stimulation with one and two extrastimuli delivered during sinus rhythm and two driven rhythms (600 and 400 msec), programmed ventricular stimulation with up to three extrastimuli and was performed in the control state and after infusion of isoproterenol. The results of programmed atrial stimulation were compared with those obtained in 36 asymptomatic subjects without heart disease and with a mean age of 50 +/- 18 years (control group). Sustained SVTA (> 1 minute) was induced in seven of eight patients with spontaneous SVTA, in 27 (69%) of those with ARVD, who did not have spontaneous SVTA, and in two control subjects (5.5%) (p < 0.001). SVTA was inducible in the control state, but ventricular tachycardia induction required isoproterenol in 11 of 27 patients. Two patients without SVTA history but with inducible SVTA developed later spontaneous SVTA. ARVD was associated with a significantly higher incidence of inducible SVTA than in a control population. Supraventricular tachycardias may precede ventricular tachycardias. This association argues for a diffuse myocardial disorder in ARVD.
authors.affiliation: Cardiology A, CHU of Brabois, Vandoeuvre les Nancy, France.
authors.forename: B
authors.initials: B
authors.lastname: Brembilla-Perrot
authors.forename: L
authors.initials: L
authors.lastname: Jacquemin
authors.forename: P
authors.initials: P
authors.lastname: Houplon
authors.forename: P
authors.initials: P
authors.lastname: Houriez
authors.forename: D
authors.initials: D
authors.lastname: Beurrier
authors.forename: V
authors.initials: V
authors.lastname: Berder
authors.forename: A
authors.initials: A
authors.lastname: Terrier de la Chaise
authors.forename: P
authors.initials: P
authors.lastname: Louis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002304:Cardiac Pacing, Artificial; D002316:Cardiotonic Agents; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D004719:Endomyocardial Fibrosis / Q000150:complications* / Q000503:physiopathology; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D007545:Isoproterenol; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013617:Tachycardia, Supraventricular / Q000209:etiology* / Q000503:physiopathology; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000503:physiopathology; D018497:Ventricular Dysfunction, Right / Q000150:complications* / Q000503:physiopathology
chemical_list: D002316:Cardiotonic Agents; D007545:Isoproterenol